文献速递血栓与止血造血干细胞移植与细胞治疗

异基因造血干细胞移植存活者迟发性静脉血栓栓塞风险:BMTSS-HiGHS2风险模型

Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model.
PubMed 文献 · Blood Adv · 2021-01-01

该回顾性队列研究基于BMTSS,纳入1974至2014年间移植且存活≥2年的1554例异基因BMT存活者,与907名同胞比较,发现存活者VTE风险为同胞的7.3倍。中位随访11年,移植后5年、10年、20年迟发性VTE累积发生率分别为2.4%、4.9%、7.1%。构建的HiGHS2模型(含卒中史、慢性GVHD、高血压、性别、干细胞来源)可区分高、低危患者,10年累积发生率分别为9.3%和2.4%。

要点

  • 异基因BMT存活者VTE风险显著高于同胞,达7.3倍。
  • 迟发性VTE累积发生率随时间上升,20年达7.1%。
  • HiGHS2模型可在移植后2年识别高危患者,指导靶向预防。

核心结论

  • 异基因BMT存活者迟发性VTE风险显著增高,HiGHS2模型可用于风险分层。

研究设计与样本

  • 回顾性队列研究BMTSS,纳入1974-2014年移植且存活≥2年的1554例异基因BMT存活者,对照为907名同胞。

主要发现

  • 异基因BMT存活者VTE风险为同胞的7.3倍(95%CI 4.69-11.46;P<.0001)。
  • 中位随访11年,移植后5年、10年、20年迟发性VTE累积发生率分别为2.4%、4.9%、7.1%。
  • HiGHS2模型校正C统计量为0.73(95%CI 0.67-0.79),可区分高、低危患者,10年累积发生率分别为9.3%和2.4%(P<.0001)。

关键数值与推荐

  • HiGHS2模型纳入移植后2年时的卒中史、慢性GVHD、高血压、性别(男vs女)和干细胞来源(外周血干细胞vs其他)。

临床怎么用

  • 移植后2年应用HiGHS2模型可识别迟发性VTE高危患者,辅助制定靶向预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic blood or marrow transplant (BMT) recipients are at risk for venous thromboembolism (VTE) because of high-intensity therapeutic exposures, comorbidities, and a proinflammatory state due to chronic graft-versus-host disease (GVHD). The long-term risk of VTE in allogeneic BMT survivors remains unstudied. Participants were drawn from the Blood or Marrow Transplant Survivor Study (BMTSS), a retrospective cohort study that included patients who underwent transplantation between 1974 and 2014 and survived ≥2 years after BMT. We analyzed the risk of VTE in 1554 2-year survivors of allogeneic BMT compared with 907 siblings. Using backward variable selection guided by minimizing Akaike information criterion, we created a prediction model for risk of late-occurring VTE. Allogeneic BMT survivors had a 7.3-fold higher risk of VTE compared with siblings (95% CI, 4.69-11.46; P < .0001). After a median follow-up of 11 years, conditional on surviving the first 2 years after BMT, the cumulative incidence of late-occurring VTE was 2.4% at 5 years, 4.9% at 10 years, and 7.1% at 20 years after BMT. The final model for VTE risk at 2 years post-BMT included History of stroke, chronic GVHD, Hypertension, Sex (male vs female) and Stem cell source (peripheral blood stem cells vs other) ("HiGHS2") (corrected C-statistics: 0.73; 95% CI = 0.67-0.79). This model was able to classify patients at high and low VTE risk (10-year cumulative incidence, 9.3% vs 2.4% respectively; P < .0001). The BMTSS HiGHS2 risk model when applied at 2 years post-BMT can be used to inform targeted prevention strategies for patients at high risk for late-occurring VTE.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gangaraju R, Chen Y, Hageman L, et al. Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model. Blood Adv. 2021. PMID: 34461633. doi:10.1182/bloodadvances.2021004341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。